Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjusted Comparison of First-line Enfortumab Vedotin Plus Pembrolizumab Versus Platinum-based Chemotherapy ± Avelumab Maintenance for the Treatment of Locally Advanced/Metastatic Urothelial Carcinoma.

European urology oncology·2026
Same author

Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.

European journal of cancer (Oxford, England : 1990)·2026
Same author

A pure intertubular testicular seminoma mimicking a burned-out tumor: a case report.

Frontiers in oncology·2026
Same author

Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study.

Cancer immunology, immunotherapy : CII·2026
Same author

Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors.

Frontiers in oncology·2026

Related Experiment Video

Updated: Jun 6, 2025

Transgenic Rodent Assay for Quantifying Male Germ Cell Mutant Frequency
14:45

Transgenic Rodent Assay for Quantifying Male Germ Cell Mutant Frequency

Published on: August 6, 2014

16.3K

French AFU Cancer Committee Guidelines - Update 2024-2026: Testicular germ cell cancer.

Thibaut Murez1, Aude Fléchon2, Nicolas Branger3

  • 1Comité de Cancérologie de l'Association Française d'Urologie, groupe organes génitaux externes, Maison de l'Urologie, 11, rue Viète, 75017 Paris, France; Department of Urology and Renal Transplantation, CHU de Montpellier, 371, avenue du Doyen-Gaston-Giraud, 34295 Montpellier cedex 5, France.

The French Journal of Urology
|November 24, 2024
PubMed
Summary

Updated guidelines for testicular germ cell tumours (GCT) management emphasize surveillance for stage I seminoma and risk-adapted strategies for nonseminoma. Treatment for metastatic GCT involves chemotherapy, yielding excellent survival rates.

Keywords:
BEPChemotherapyOrchiectomyRadiotherapyRetroperitoneal lymph node dissectionTesticular cancer

More Related Videos

A Sensitive Method to Quantify Senescent Cancer Cells
09:18

A Sensitive Method to Quantify Senescent Cancer Cells

Published on: August 2, 2013

20.6K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

Related Experiment Videos

Last Updated: Jun 6, 2025

Transgenic Rodent Assay for Quantifying Male Germ Cell Mutant Frequency
14:45

Transgenic Rodent Assay for Quantifying Male Germ Cell Mutant Frequency

Published on: August 6, 2014

16.3K
A Sensitive Method to Quantify Senescent Cancer Cells
09:18

A Sensitive Method to Quantify Senescent Cancer Cells

Published on: August 2, 2013

20.6K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

Area of Science:

  • Oncology
  • Urology

Background:

  • Testicular germ cell tumours (GCT) are the most common cancer in young men.
  • Accurate diagnosis and staging are crucial for effective management.

Purpose of the Study:

  • To provide updated recommendations for the diagnosis, treatment, and follow-up of testicular germ cell tumours.
  • To review the safety and efficacy of current treatment modalities.

Main Methods:

  • A comprehensive PubMed literature review was conducted for studies published in 2022.
  • The evidence level of included studies was assessed to inform recommendations.

Main Results:

  • Initial assessment involves clinical, biological (AFP, hCG, LDH), and radiological (ultrasound, CT) evaluation.
  • Stage I seminoma management favors surveillance or carboplatin chemotherapy; stage I nonseminoma options include surveillance or risk-adapted chemotherapy (bleomycin, etoposide, cisplatin [BEP]).
  • Metastatic GCT treatment relies on BEP chemotherapy, with treatment duration based on IGCCCG prognostic groups. Surgery is rarely indicated for residual masses.

Conclusions:

  • Adherence to updated GCT management guidelines leads to high survival rates.
  • Excellent survival rates of 99% for stage I and over 85% for metastatic GCT are achievable.